European regulators back Blueprint’s Ayvakyt for stomach tumoursEuropean regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain Share XEuropean regulators back Blueprint’s Ayvakyt for stomach tumourshttps://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/
